Mumbai: Marksans Pharma Ltd. has completed the acquisition of a manufacturing site from Tevapharm
India in Plot No. Al, Phase l-A, Verna Industrial Estate, Verna, Goa 403722, India. The acquisition was first
announced in October 2022.
With the completion of the acquisition, Marksans will start operating at the acquired facility. As a part of
the agreement, Marksans will continue to supply existing products until the end of 2023 to Teva’s affiliates,
ensuring high-quality standards.
The contract manufacturing agreement with Teva is to continue providing
an uninterrupted supply of Teva’s important medicines to customers and patients. Marksans has retained
the transferring employees on terms materially similar to its current employment. Teva’s adjoining Watson
Pharma Private Limited’s site is not part of the divestment with Marksans and will remain with Teva.
The acquired facility will enable Marksans Pharma to potentially double the existing Indian capacity from
8bn units per annum currently. It is a scalable capacity to manufacture oral solid dosage forms. Marksans
plans to manufacture tablets, hard and soft gel capsules, ointments, liquids, and creams, from the new
capacity. The manufacturing site is spread across 47,597 square meters and has approvals to manufacture
products from the EU, Health Canada & Japanese Health Authority.
Commenting on the acquisition, Mark Saldanha, Managing Director of the Company said, “The completion
of the manufacturing capacity from Tevapharm India is a significant milestone to strengthen our position as
a leading low-cost manufacturer and to provide high-quality products to meet the growing demands of our
customers. It will accelerate the growth of our business while expanding our product base and market share
gains. We remain committed to investing in our future, and this will set the stage for the next phase of our
growth journey.”
Read also: USFDA nod to Marksans Pharma Famotidine Tablets for OTC use
GIPHY App Key not set. Please check settings